attendees.bizzabo.com
Open in
urlscan Pro
2606:4700::6812:1634
Public Scan
Submitted URL: https://u29002428.ct.sendgrid.net/ls/click?upn=fQFYBBQ6qHesxPRxeHpraPj-2FZ-2BDnkZNTLf6Nmzj3XIVNiNmfhawMBSxuJlPAJY3Gikaym4dJZtDIeIi...
Effective URL: https://attendees.bizzabo.com/536217?source=magic_link
Submission: On December 06 via api from DE — Scanned from DE
Effective URL: https://attendees.bizzabo.com/536217?source=magic_link
Submission: On December 06 via api from DE — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
You need to enable JavaScript to run this app. * Agenda * More Info More 09.13 09.14 Favorites 9:00AM Your Local Time (GMT+1) 3hr 40min. Watch Recording Day 2 - first session * 09:00–09:05 Opening remarks from QIAGEN * 09:05–09:40 Presentation Comprehensive evaluation for risk classification and treatment selection for Ph- ALL Speaker: Dr. Nicola Gökbuget, University Hospital Frankfurt, Germany * 09:40–10:15 Presentation MRD as a tool to evaluate treatment response and predict relapse in Ph+ ALL Speaker: Dr. Rathana Kim, Department of Molecular Hematology, Hematology Laboratory, Hôpital Saint-Louis, Paris, France * 10:15–10:50 Presentation Importance of testing in multiple myeloma Speaker: Dr. Claudio Cerchione, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" – IRST IRCCS, Meldola, Italy * 10:50–11:25 Presentation A conversation with Prof. Albrecht Stenzinger: IVDR strategy Speaker: Prof. Albrecht Stenzinger, Institute of Pathology, University Hospital Heidelberg, Germany * 11:25–12:40 Lunch and networking Read more * 09:00–09:05 Opening remarks from QIAGEN * 09:05–09:40 Presentation Comprehensive evaluation for risk classification and treatment selection for Ph- ALL Speaker: Dr. Nicola Gökbuget, University Hospital Frankfurt, Germany * 09:40–10:15 Presentation MRD as a tool to evaluate treatment response and predict relapse in Ph+ ALL Speaker: Dr. Rathana Kim, Department of Molecular Hematology, Hematology Laboratory, Hôpital Saint-Louis, Paris, France * 10:15–10:50 Presentation Importance of testing in multiple myeloma Speaker: Dr. Claudio Cerchione, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" – IRST IRCCS, Meldola, Italy * 10:50–11:25 Presentation A conversation with Prof. Albrecht Stenzinger: IVDR strategy Speaker: Prof. Albrecht Stenzinger, Institute of Pathology, University Hospital Heidelberg, Germany * 11:25–12:40 Lunch and networking Read more 12:40PM Your Local Time (GMT+1) 2hr 45min. Watch Recording Day 2 - second session * 12:40–13:15 Presentation JAK2 V617F monitoring in MPN Speaker: Prof. Jean-Jacques Kiladjian, Clinical Investigations Center, Saint-Louis Hospital & the University of Paris, Paris, France * 13:15–13:50 Presentation Using molecular testing to detect biomarker heterogeneity within MPN Speaker: Dr. Bruno Cassinat, Department of Cell Biology, Saint-Louis Hospital, Paris, France * 13:50–14:25 Presentation Approaches to select patients for CAR T-cell therapy Speaker: Dr. Jae Hong Park, Memorial Sloan Kettering Cancer Center, New York, USA * 14:25–15:10 Patient perspective A testimonial from a cancer survivor on CAR T-cell therapy Speaker: Tom Whitehead, Co-founder of the Emily Whitehead Foundation, Philipsburg, USA * 15:10–15:25 Closing remarks from QIAGEN Read more * 12:40–13:15 Presentation JAK2 V617F monitoring in MPN Speaker: Prof. Jean-Jacques Kiladjian, Clinical Investigations Center, Saint-Louis Hospital & the University of Paris, Paris, France * 13:15–13:50 Presentation Using molecular testing to detect biomarker heterogeneity within MPN Speaker: Dr. Bruno Cassinat, Department of Cell Biology, Saint-Louis Hospital, Paris, France * 13:50–14:25 Presentation Approaches to select patients for CAR T-cell therapy Speaker: Dr. Jae Hong Park, Memorial Sloan Kettering Cancer Center, New York, USA * 14:25–15:10 Patient perspective A testimonial from a cancer survivor on CAR T-cell therapy Speaker: Tom Whitehead, Co-founder of the Emily Whitehead Foundation, Philipsburg, USA * 15:10–15:25 Closing remarks from QIAGEN Read more Messages